Advertisement
 
Skip navigation links
About Us
Members
Fellows in Training
Allied Health Professionals
Alliance
Patients & Public
ACAAI Foundation
Newsroom
Sponsors
Annual Meeting
Skip navigation links
About Us Home Page
The Specialty
American Medical Association Code of Ethics
Membership Categories | Membership in ACAAI
Become a Member
Become an International Affiliate Member
College History, Leadership & Awards
ACAAI Privacy Policy
ACAAI Terms of Use
Contact Us
Non-Members Online Store
iCAALL
Medical Student Resources
Clinical Trial Resource
  
 
Clinical Trial Resource
Welcome to the ACAAI Clinical Trial Resource page which connects physicians to existing clinical trials in allergy, asthma and immunology led by our pharmaceutical partners. Involvement in clinical trials provides the opportunity to further medical research and improve patient outcomes. While the ACAAI does not endorse these trials; we do encourage clinicians and their patients to partake in this valuable resource. Without these clinical trials, medical advancements would be greatly hindered.

To obtain information on how to become involved in a clinical trial, please browse the trial opportunities below.
The following trials listed are from the ACAAI 2014 Corporate Council Members.
If you are not a participating member, but would like to list your trial, 
please contact Linda Cullison at lindacullison@acaai.org.
 
A Phase II, Randomized, Double-Blind, Placebo-Controlled Bronchoscopy Study to Evaluate the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication (CLAVIER)
Company: Genentech, Inc.
Description: CLAVIER is a Phase II bronchoscopy study evaluating the effects of lebrikizumab on airway eosinophilic inflammation in patients with asthma whose disease remains uncontrolled despite guideline-based asthma therapy.
Eligible Patient: Adult patients with asthma who continue to have symptoms after receiving treatment with an inhaled corticosteroid and a second controller medication for at least 6 months may be considered for this clinical trial.
Date Posted: August 20, 2014
Learn more about this clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Company: Genentech, Inc.
Description: ACOUSTICS is a Phase III study evaluating the efficacy, safety and tolerability of lebrikizumab in adolescent patients with asthma whose disease remains uncontrolled despite guideline-based asthma therapy.
Eligible Patient: Adolescent (12-17 years) patients with asthma who continue to have symptoms after receiving treatment with an inhaled corticosteroid and a second controller medication for at least 6 months may be considered for this clinical trial.
Date Posted: August 20, 2014
Learn more about this clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
Company: Genentech, Inc.
Description: STRETTO is a Phase III study assessing the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist therapy alone.
Eligible Patient: Adult patients with stable asthma diagnosed at least 12 months ago who are not treated with inhaled corticosteroids or other controller medications may be considered for this clinical trial.
Date Posted: August 20, 2014
Learn more about this clinical trial
 
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Assess the Oral Corticosteroid-Sparing Effect of Lebrikizumab in Patients with Severe Corticosteroid-Dependent Asthma
Company: Genentech, Inc.
Description: VOCALS is a Phase II study evaluating the efficacy of lebrikizumab as measured by the ability to achieve lower daily doses of oral corticosteroids in patients with severe corticosteroid-dependent asthma.
Eligible Patient: Adult patients with severe asthma despite intensive follow-up by an asthma specialist and on chronic treatment with maintenance oral corticosteroids for at least 6 months may be considered for this trial.
Date Posted: August 20, 2014
Learn more about this clinical trial
 
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Company: Genentech, Inc.
Description: RIFF is a Phase II study evaluating the safety and efficacy of lebrikizumab in patients with IPF. The primary outcome measure for the study is Progression Free Survival.
Eligible Patient: Adult patients ≥ 40 years of age with a definite diagnosis of IPF according to the 2011 ATS/ERS/JRS/ALAT consensus statement on IPF within the previous 4 years from the time of screening.
Date Posted: August 20, 2014
Learn more about this clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma who are on Inhaled Corticosteroids and a Second Controller Medication (LAVOLTA I and LAVOLTA II)
Company: Genentech, Inc.
Description: LAVOLTA I and LAVOLTA II are two parallel Phase 3 studies designed to evaluate the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite treatment with guideline-based asthma therapy.
Eligible Patient: Adult patients with asthma who continue to have symptoms after receiving treatment with an inhaled corticosteroid and a second controller medication for at least 6 months may be considered for these clinical trials.
Date Posted: August 20, 2014
Lavolta I:I Learn more about this clinical trial
Lavolta II: Learn more about this clinical trial
 
Copyright 2012 - American College of Allergy, Asthma & Immunology | 85 West Algonquin Road, Suite 550 | Arlington Heights, IL 60005











website designed and maintained by Washington Graphic Services